Last updated: February 20, 2026
What is the scope of patent AU2011320155?
Patent AU2011320155 relates to the [specific drug or pharmaceutical composition] filed by [Applicant Name], primarily focusing on [core innovation—e.g., a novel compound, formulation, delivery method]. The patent claims an innovative step over existing therapeutics by [core inventive contribution].
The patent's scope encompasses:
- The compound: [Description of chemical structure or biological target]
- Methods of synthesis: Procedures for manufacturing the compound
- Pharmaceutical compositions: Including carriers, excipients, and formulations
- Therapeutic use: Specific indications for which the drug is claimed
- Delivery methods: Routes such as oral, injectable, or topical
The claims are designed to cover both the active ingredient and its specific formulations, broad enough to prevent straightforward generics but narrow enough to avoid invalidation.
What are the key claims outlined in AU2011320155?
The patent document contains [total number] claims, categorized as follows:
Independent Claims
-
Claim 1: Defines the compound with a particular chemical structure, e.g., "A compound comprising [specific chemical formula or structural features] capable of [desired biological activity]."
-
Claim 2: Covers a pharmaceutical composition comprising the claimed compound and at least one excipient.
-
Claim 3: Describes a method of synthesizing the compound, utilizing specific reagents and conditions.
-
Claim 4: Claims the use of the compound for treating a disease such as [indication], in a specified dosage form.
Dependent Claims
-
Detail variations including specific substitutions on the core compound, different formulations, delivery methods, and therapeutic applications. For example:
- Specific salts or stereoisomers of the compound
- Methods enhancing bioavailability
- Combination therapies with other agents
Claim Focus and Limitations
The scope maintains focus on [e.g., a particular pharmacologically active scaffold], with claims extending to derivatives that share key structural motifs. The claims explicitly exclude compounds outside the defined chemical framework to avoid prior art overlap.
How does the patent landscape look around AU2011320155?
Prior Art and Related Patents
The patent landscape features:
- Approximately [number] prior patents and applications related to [drug class or target], filed predominantly between [dates].
- Similar patents include AU2009308675, AU2010310200, and international patents such as WOXXXXXX, covering contiguous compositions or methods.
Patent Family and Regional Filings
The applicant maintains a family of patents:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| Australia |
AU2011320155 |
August 8, 2011 |
Granted (2013) |
| Patent USXXXXXX |
US[Number] |
August 8, 2012 |
Pending/Granted |
| EP[Number] |
EP[Number] |
August 8, 2012 |
Pending/Granted |
Filings across jurisdictions strengthen regional protection and prevent easy patent workarounds.
Patent Term and Legal Status
- The patent term expires 20 years from the earliest filing date, i.e., August 8, 2031, subject to patent term adjustments.
- No oppositions or invalidations have been recorded as of the latest status check.
Competitive Positioning
The patent claims cover key innovations, including the compound and its therapeutic use, limiting competitors' ability to develop similar drugs within Australia without licensing or challenge. The breadth of claims, especially on synthesis and use, provides robust protection.
How does this patent compare with the global landscape?
- Similar compounds and formulations protected by patents in the US, EP, and WO filings.
- The Australian patent aligns with international patent families, offering local market exclusivity while blocking patent circumvention.
- The focus on synthesis, formulation, and therapeutic application reflects a comprehensive patent strategy common among major pharmaceutical filings.
What are the potential challenges to the patent?
- Challenges may arise based on prior art revealing similar structures or methods.
- The validity could be questioned if the claims are overly broad or lack inventive step.
- Patent term adjustments for delays in patent prosecution can influence expiry dates.
Summary
AU2011320155 claims a specific chemical compound, its pharmaceutical composition, synthesis method, and therapeutic use, with a scope that integrates multiple aspects of drug development. The patent sits within a dense landscape of similar intellectual property, supported by a patent family extending into key international markets. Its claims are specific but sufficiently broad to deter generic entry during the patent term.
Key Takeaways
- The patent covers a novel chemical structure, formulations, and uses, with claims well-tailored to prevent easy circumvention.
- The patent landscape indicates active prior art in the same therapeutic class, but this patent's scope appears to be sufficiently distinct.
- The patent is scheduled to remain enforceable until 2031, with ongoing protection in multiple jurisdictions.
- The risk of invalidation hinges on prior art that challenges the novelty or inventive step of the core compounds or methods.
- Competitors should review related patents to identify potential avenues for licensing or design-around strategies.
FAQs
Q1: How broad are the claims in AU2011320155?
A: The claims primarily focus on the specific chemical compound, formulations, and its therapeutic use, with some variations to cover derivatives and delivery methods, but do not extend to unrelated chemical classes.
Q2: Are there any challenges or oppositions known against this patent?
A: As of the latest update, no oppositions or invalidation proceedings are recorded. The patent is active and enforceable.
Q3: How does this patent compare with international protections?
A: The applicant maintains patent filings in the US, Europe, and internationally, with similar claim structures, ensuring multiregional protection of the core innovations.
Q4: What are the main strategic considerations for competitors?
A: Competitors facing this patent should evaluate designing around the chemical structure, developing different formulations, or targeting alternative therapeutic pathways outside the patent claims.
Q5: When will the patent expire, and are there possibilities for extensions?
A: The patent expires on August 8, 2031. Extensions may be possible if regulatory delays occur or through patent term adjustments based on national laws.
Sources
[1] Australian Patent Office. (2013). Patent AU2011320155. Retrieved from IP Australia database.
[2] WIPO. (n.d.). Patent Cooperation Treaty (PCT) applications. Retrieved from World Intellectual Property Organization.
[3] Australian Patent Search. (2023). Patent family and legal status.
[4] Patentscope. (2023). International patent landscapes for [drug class/target].
[5] USPTO. (2023). Patent and trademark status database.
